Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Novartis
Centre Antoine Lacassagne
Nagoya City University
AstraZeneca
Novartis
Hoffmann-La Roche
Pfizer
Eli Lilly and Company
Forward Pharmaceuticals Co., Ltd.
Stemline Therapeutics, Inc.
Big Ten Cancer Research Consortium
Avenzo Therapeutics, Inc.
Jonsson Comprehensive Cancer Center
Dana-Farber Cancer Institute
Yonsei University
Novartis